Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats.
Although cardiac hypertrophy in hypertension has been well recognized, the molecular mechanisms for the development of hypertrophy are still largely unknown. In this study, the protein expression profiles of left ventricular myocardia in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats at different ages were analyzed using 2-DE in combination with MALDI-TOF/TOF MS/MS. The results showed that 20 proteins were modulated in the hypertrophic myocardium. Out of these modulated proteins, 13 proteins presented significant changes in SHR at an early stage prior to the development of sustained hypertension, while the changes of the other 7 protein expressions occurred only at a late stage in SHR when the blood pressure was significantly elevated, and were largely reversible by treatment with rennin-angiotensin-aldosterone system inhibitors losartan or enalapril. These data demonstrate that the changes in energy metabolism in the hypertrophied heart favor an increase in glycolysis and a decrease in oxidation of fatty acid and glucose, which occur at an early stage in SHR without hypertension. Our results also provide evidence to support the hypothesis that oxidative stress plays an important role in the development of hypertensive cardiac hypertrophy.
Jin
Xian
X
Department of Geriatrics, Ren-Ji Hospital, Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education [corrected] Shanghai Jiao-Tong University Medical School, Shanghai, PR China.
Xia
Li
L
Wang
Li-Shun
LS
Shi
Jun-Zhi
JZ
Zheng
Ying
Y
Chen
Wen-Li
WL
Zhang
Lei
L
Liu
Zhen-Guo
ZG
Chen
Guo-Qiang
GQ
Fang
Ning-Yuan
NY
D000367:Age Factors; D000375:Aging / Q000502:physiology*; D000465:Algorithms; D000818:Animals; D000959:Antihypertensive Agents; D015153:Blotting, Western; D006332:Cardiomegaly / Q000378:metabolism*; D016208:Databases, Factual; D015180:Electrophoresis, Gel, Two-Dimensional; D004656:Enalapril / Q000494:pharmacology; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D019808:Losartan / Q000494:pharmacology; D008297:Male; D013058:Mass Spectrometry; D009206:Myocardium / Q000378:metabolism; D010449:Peptide Mapping; D011506:Proteins / Q000032:analysis / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014357:Trypsin / Q000494:pharmacology
D000959:Antihypertensive Agents; D011506:Proteins; D004656:Enalapril; D014357:Trypsin; D019808:Losartan